Mostrar el registro sencillo del ítem
| dc.contributor.author | de-los-Santos, Ignacio | |
| dc.contributor.author | Pousada, Guillermo | |
| dc.contributor.author | Galera-Peñaranda, Carlos | |
| dc.contributor.author | Duenas, Carlos | |
| dc.contributor.author | Buzon, Luis | |
| dc.contributor.author | Sanz, José | |
| dc.contributor.author | Martin, Cristina | |
| dc.contributor.author | Garcinuno, María-Ángeles | |
| dc.contributor.author | Galindo, María-José | |
| dc.contributor.author | García-Fraile, Lucio | |
| dc.contributor.author | Pedrero-Tome, Roberto | |
| dc.contributor.author | Troya, Jesús | |
| dc.date.accessioned | 2026-11-11T09:05:36Z | |
| dc.date.available | 2026-11-11T09:05:36Z | |
| dc.date.issued | 2026-01 | |
| dc.identifier.citation | De Los Santos I, Pousada G, Galera C, Dueñas C, Buzón L, Sanz J, et al. Clinical Outcomes of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living With HIV and Low-Level Viraemia. J Int Assoc Provid AIDS Care. enero de 2026;25:23259582261482031. doi:10.1177/23259582261482031 | |
| dc.identifier.issn | 2325-9574 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/29179 | |
| dc.description.abstract | IntroductionLow-level viraemia (LLV) in people living with HIV (PLWH) remains a clinical challenge, associated with increased risk of virological failure, immune dysregulation, and chronic inflammation. Bictegravir/emtricitabine/tenofovir alafenamide is a single-tablet regimen with a high genetic barrier to resistance, but real-world outcomes after switching in PLWH with LLV remain insufficiently characterized. This study aimed to describe virological, immunological, metabolic, and safety outcomes after switching to bictegravir/emtricitabine/tenofovir alafenamide in PLWH with documented LLV over 96 weeks.MethodsA retrospective, multicentre study was conducted across 12 Spanish healthcare centres. PLWH aged ?18 years with a documented qualifying LLV episode before switch (two consecutive HIV-1 RNA measurements between 50 and 400 copies/mL) who switched to bictegravir/emtricitabine/tenofovir alafenamide were included (N = 123). Outcomes included virological suppression (<50 copies/mL), residual LLV, CD4+/CD8+ dynamics, metabolic changes, and safety. Analyses were descriptive, used observed denominators, and included a non-completer=failure sensitivity analysis for virological suppression.ResultsAmong participants (median age: 52 years, 80.5% male; median time since HIV diagnosis: 30 years), observed LLV decreased to 11.4% (13/114 patients) at 96 weeks after switching to bictegravir/emtricitabine/tenofovir alafenamide (p<0.001). In the non-completer=failure sensitivity analysis, virological suppression at week 96 was 82.1% (101/123). At week 96, all detectable HIV-1 RNA values were 55-272 copies/mL; 3/13 patients had LLV at all available 24-, 48-, and 96-week visits. CD4+/CD8+ ratios remained stable, with a significant reduction in CD8+ T cell counts in patients ?50 years. Biochemical markers were broadly stable, but weight/BMI increases and a shift toward overweight were observed and warrant monitoring. No treatment discontinuations due to adverse events were reported.ConclusionIn this single-arm retrospective cohort, switching to bictegravir/emtricitabine/tenofovir alafenamide was associated with a high observed proportion of virological suppression, immune stability, and favourable tolerability over 96 weeks; however, causal effectiveness cannot be inferred. These findings support further comparative prospective evaluation of bictegravir/emtricitabine/tenofovir alafenamide for LLV management. | |
| dc.language.iso | eng | |
| dc.publisher | SAGE PUBLICATIONS INC | |
| dc.rights | Atribución/Reconocimiento-NoComercial 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/deed.es | * |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Adenine/analogs & derivatives/therapeutic use | |
| dc.subject.mesh | Alanine | |
| dc.subject.mesh | Amides | |
| dc.subject.mesh | Anti-HIV Agents/therapeutic use | |
| dc.subject.mesh | CD4 Lymphocyte Count | |
| dc.subject.mesh | Drug Substitution | |
| dc.subject.mesh | Emtricitabine/therapeutic use | |
| dc.subject.mesh | Heterocyclic Compounds, 4 or More Rings/therapeutic use | |
| dc.subject.mesh | HIV Infections/drug therapy/virology | |
| dc.subject.mesh | HIV-1/drug effects | |
| dc.subject.mesh | Pyridones/therapeutic use | |
| dc.subject.mesh | Retrospective Studies | |
| dc.subject.mesh | Spain | |
| dc.subject.mesh | Tenofovir/therapeutic use/analogs & derivatives | |
| dc.subject.mesh | Treatment Outcome | |
| dc.subject.mesh | Viral Load | |
| dc.subject.mesh | Viremia/drug therapy | |
| dc.subject.mesh | Heterocyclic Compounds, 3-Ring | |
| dc.subject.mesh | Piperazines | |
| dc.title | Clinical Outcomes of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People Living With HIV and Low-Level Viraemia | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42874079 | |
| dc.relation.publisherversion | https://journals.sagepub.com/doi/10.1177/23259582261482031 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1177/23259582261482031 | |
| dc.journal.title | Journal of the International Association of Providers of Aids Care | |
| dc.identifier.essn | 2325-9582 |